

Information for Colorado Prescribers of Prescription Drugs EBGLYSS™ (lebrikizumab-lbkz)

- Lilly USA LLC's Wholesale Acquisition Cost (WAC) is the listed price to the distribution channel not including prompt pay, service or administrative fees, stocking or distribution allowances, or any discounts, rebates, or chargebacks provided by Lilly USA to any entity.
- The products listed below represent the first generic products to market from the same therapeutic class as the Marketed Product (as determined by the USC therapeutic classification).^{1,2} This list is limited to three products and is not necessarily inclusive of all generic alternatives available.
- This list of generic products below does not imply that the products are interchangeable or have the same efficacy or safety as the Marketed Product. Please refer to each product's FDA-approved label and indication for further information.

Marketed Product:

BRAND NAME	GENERIC NAME	STRENGTH	DOSAGE FORM	PACK SIZE	NDC	WHOLESALE ACQUISITION COST ¹
EBGLYSS™	Lebrikizumab -lbkz	250MG/2ML	Prefilled Pen	1	0002-7772-11	\$3,500.00
		250MG/2ML	Prefilled Syringe	1	0002-7797-11	\$3,500.00

Generic Product(s):

No USC Classification at this time.³

EBGLYSS™ and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

All trademarks are the property of their respective owners.

¹ Source: AnalySource®. Accessed on 09/16/2024. WAC reprinted with permission by First Databank Inc. All rights reserved. © 2024. <http://www.fdbhealth.com/policies/drug-pricing-policy/>.

² For some biologics, such as insulins, unbranded products are included in the list of "Generic Product(s)" if identified as "generics" in AnalySource®.

³ Represents the USC classification of the marketed product. <https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-uniform-system-of-classification.pdf?la=en&hash=91EF697FDBFC81DF57A0EC816CA83E1BCC82DB28>.